Imiquimod

Mechanism :

Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma, it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion.

Indication :

• Condyloma acuminate
• Genital HSV, antiviral-resistant

Contraindications :

Hypersensitivity to drug/class/component. Caution if pre-existing autoimmune disorders, inflamed skin at application site, photosensitivity.

Dosing :

Adverse Effect :

Common Reactions: Local inflammatory reaction, application site reaction, headache, influenza-like symptoms, anorexia, dizziness, herpes simplex, pain, chest pain, diarrhea, lymphadenopathy, dyspepsia.

Serious Reactions: Exfoliative dermatitis, erythema multiforme, urinary retention.

Interaction :

No known drug interactions.

Hepatic Dose :